Hoppa till innehållet

Västra Hamnen Market Focus: Bioextrax: Sweet dreams of a bright 2024
  • Joint Development Agreement with the candy producer in Q1
  • Progression in several projects, funding risk remains
  • Our model implies a fair valuation of SEK 7.60 per share

A quiet final quarter of 2023 was followed by an eventful start of 2024 for Lund-based Bioextrax. In January, the American startup terminated the contract due to financial issues. For Bioextrax, the financial impact of the cancellation was limited according in our valuation model. However, the stock market reaction on the news was harsh sending the share price down by 30 per cent.

The initial research report is available here.

Source:MFN
Tillbaka

Det verkar som att du använder en annonsblockerare

Om du är prenumerant behöver du logga in för att fortsätta. Vill du bli prenumerant kan du läsa Di Digitalt för 197 kr inkl. moms de första 3 månaderna.

spara
1180kr
Prenumerera